Jorge R Barrio

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi request reprint Dissecting molecular mechanisms in the living brain of dementia patients
    Jorge R Barrio
    Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA
    Acc Chem Res 42:842-50. 2009
  2. ncbi request reprint A rational regulatory approach for positron emission tomography imaging probes: from "first in man" to NDA approval and reimbursement
    Jorge R Barrio
    Department of Molecular and Medical Pharmacology, The David Geffen UCLA School of Medicine, Los Angeles, CA 90095 6948, USA
    Mol Imaging Biol 6:361-7. 2004
  3. pmc Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at the University of California, Los Angeles, CA 90024, USA
    Am J Geriatr Psychiatry 16:999-1009. 2008
  4. pmc Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia
    Gary W Small
    Semel Institute, 760 Westwood Plaza, Ste 88 201, Los Angeles, CA 90024, USA
    Arch Gen Psychiatry 66:81-7. 2009
  5. pmc Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region
    Koon Pong Wong
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Rm B2 085E CHS, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Eur J Nucl Med Mol Imaging 37:575-88. 2010
  6. pmc Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults
    Helen Lavretsky
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095 9668, USA
    Am J Geriatr Psychiatry 17:493-502. 2009
  7. ncbi request reprint PET of brain amyloid and tau in mild cognitive impairment
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and the Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at the University of California, Los Angeles, USA
    N Engl J Med 355:2652-63. 2006
  8. pmc Differential FDDNP PET patterns in nondemented middle-aged and older adults
    Linda M Ercoli
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095 9668, USA
    Am J Geriatr Psychiatry 17:397-406. 2009
  9. ncbi request reprint Imaging beta-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization
    Kooresh Shoghi-Jadid
    Department of Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1766, USA
    Nucl Med Biol 32:337-51. 2005
  10. pmc Prediction of cognitive decline by positron emission tomography of brain amyloid and tau
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA 90024, USA
    Arch Neurol 69:215-22. 2012

Detail Information

Publications55

  1. doi request reprint Dissecting molecular mechanisms in the living brain of dementia patients
    Jorge R Barrio
    Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California 90095, USA
    Acc Chem Res 42:842-50. 2009
    ....
  2. ncbi request reprint A rational regulatory approach for positron emission tomography imaging probes: from "first in man" to NDA approval and reimbursement
    Jorge R Barrio
    Department of Molecular and Medical Pharmacology, The David Geffen UCLA School of Medicine, Los Angeles, CA 90095 6948, USA
    Mol Imaging Biol 6:361-7. 2004
    ..Equally importantly, this approach would facilitate the use of molecular imaging in drug discovery and development, which would substantially reduce the costs and time required to bring new therapeutic drugs to market...
  3. pmc Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at the University of California, Los Angeles, CA 90024, USA
    Am J Geriatr Psychiatry 16:999-1009. 2008
    ....
  4. pmc Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia
    Gary W Small
    Semel Institute, 760 Westwood Plaza, Ste 88 201, Los Angeles, CA 90024, USA
    Arch Gen Psychiatry 66:81-7. 2009
    ..Here we investigated whether known risk factors for Alzheimer disease and dementia are associated with FDDNP-PET binding...
  5. pmc Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region
    Koon Pong Wong
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Rm B2 085E CHS, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA
    Eur J Nucl Med Mol Imaging 37:575-88. 2010
    ..Subcortical white matter is known to be relatively unaffected by amyloid deposition in Alzheimer's disease (AD). We investigated the use of subcortical white matter as a reference region to quantify [(18)F]FDDNP binding in the human brain...
  6. pmc Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults
    Helen Lavretsky
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095 9668, USA
    Am J Geriatr Psychiatry 17:493-502. 2009
    ....
  7. ncbi request reprint PET of brain amyloid and tau in mild cognitive impairment
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and the Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at the University of California, Los Angeles, USA
    N Engl J Med 355:2652-63. 2006
    ..Noninvasive methods to detect these abnormal proteins are potentially useful in developing surrogate markers for drug discovery and diagnostics...
  8. pmc Differential FDDNP PET patterns in nondemented middle-aged and older adults
    Linda M Ercoli
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles, CA 90095 9668, USA
    Am J Geriatr Psychiatry 17:397-406. 2009
    ....
  9. ncbi request reprint Imaging beta-amyloid fibrils in Alzheimer's disease: a critical analysis through simulation of amyloid fibril polymerization
    Kooresh Shoghi-Jadid
    Department of Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1766, USA
    Nucl Med Biol 32:337-51. 2005
    ....
  10. pmc Prediction of cognitive decline by positron emission tomography of brain amyloid and tau
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA 90024, USA
    Arch Neurol 69:215-22. 2012
    ..To determine whether 2-(1-{6-[(2-fluorine 18-labeled fluoroethyl)methylamino]-2-napthyl}ethylidene) malononitrile ([(18)F]FDDNP) brain regional values in individuals without dementia predict and correlate with future cognitive change...
  11. ncbi request reprint 2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease
    Eric D Agdeppa
    Department of Molecular and Medical Pharmacology, Laboratory of Structural Biology and Molecular Medicine, The David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Mol Imaging Biol 5:404-17. 2003
    ..Therefore it is anticipated that a new vision for prevention, early diagnosis and treatment of Alzheimer's disease would be rapidly developing...
  12. ncbi request reprint A tracer kinetic model for 18F-FHBG for quantitating herpes simplex virus type 1 thymidine kinase reporter gene expression in living animals using PET
    Leeta Alison Green
    The Crump Institute for Molecular Imaging, David Geffen School of Medicine at UCLA, Los Angeles, California, USA
    J Nucl Med 45:1560-70. 2004
    ..We therefore investigated tracer kinetic models for 18F-FHBG dynamic microPET data and noninvasive methods for determining blood time-activity curves in an adenoviral gene delivery model in mice...
  13. pmc Self-reported memory impairment and brain PET of amyloid and tau in middle-aged and older adults without dementia
    David A Merrill
    Division of Geriatric Psychiatry, Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, and Longevity Center, University of California, Los Angeles, CA, USA
    Int Psychogeriatr 24:1076-84. 2012
    ..Here we investigate whether degree of self-reported memory impairment is associated with FDDNP-PET binding levels in persons without dementia...
  14. ncbi request reprint Imaging progress of herpes simplex virus type 1 thymidine kinase suicide gene therapy in living subjects with positron emission tomography
    Shahriar S Yaghoubi
    Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California 90095 1770, USA
    Cancer Gene Ther 12:329-39. 2005
    ..18F]FHBG and [18F]FDG imaging data indicate that exposure of C6sr39 tumors to GCV causes the elimination of [18F]FHBG-accumulating C6sr39 cells and selects for re-growth of tumors unable to accumulate [18F]FHBG...
  15. ncbi request reprint Visualizing pathology deposits in the living brain of patients with Alzheimer's disease
    Vladimir Kepe
    Department of Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, California 90095, USA
    Methods Enzymol 412:144-60. 2006
    ..In contrast, control subjects have uniformly low levels of [F-18]FDDNP binding in all areas, which is comparable to that of cerebellum...
  16. pmc Movement correction method for human brain PET images: application to quantitative analysis of dynamic 18F-FDDNP scans
    Mirwais Wardak
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095 6948, USA
    J Nucl Med 51:210-8. 2010
    ....
  17. doi request reprint PET scanning of brain tau in retired national football league players: preliminary findings
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, Los Angeles, CA 90024, USA
    Am J Geriatr Psychiatry 21:138-44. 2013
    ....
  18. pmc Vascular risk and FDDNP-PET influence cognitive performance
    David A Merrill
    Division of Geriatric Psychiatry, Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, and Longevity Center, University of California, Los Angeles, CA, USA
    J Alzheimers Dis 35:147-57. 2013
    ..These findings suggest that even mild cerebrovascular risk may influence the extent of cognitive dysfunction in pre-dementia, along with amyloid-β and tau burden...
  19. pmc Serotonin 1A receptors in the living brain of Alzheimer's disease patients
    Vladimir Kepe
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 103:702-7. 2006
    ....
  20. pmc Regional distribution of SGLT activity in rat brain in vivo
    Amy S Yu
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Am J Physiol Cell Physiol 304:C240-7. 2013
    ..The expression of SGLTs in the brain raises questions about the potential effects of SGLT inhibitors under development for the treatment of diabetes...
  21. pmc Current and future uses of neuroimaging for cognitively impaired patients
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, USA
    Lancet Neurol 7:161-72. 2008
    ....
  22. pmc Comparative evaluation of Logan and relative-equilibrium graphical methods for parametric imaging of dynamic [18F]FDDNP PET determinations
    Koon Pong Wong
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Neuroimage 60:241-51. 2012
    ..In this work, we have characterized a relative-equilibrium-based (RE) graphical method against the Logan analysis for parametric imaging and region-of-interest (ROI) analysis...
  23. ncbi request reprint Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease
    Kooresh Shoghi-Jadid
    Division of Nuclear Medicine, UCLA School of Medicine, Los Angeles, CA, USA
    Am J Geriatr Psychiatry 10:24-35. 2002
    ..0007). This noninvasive technique for monitoring AP and NFT development is expected to facilitate diagnostic assessment of patients with AD and assist in response-monitoring during experimental treatments...
  24. pmc [F-18]FDDNP microPET imaging correlates with brain Aβ burden in a transgenic rat model of Alzheimer disease: effects of aging, in vivo blockade, and anti-Aβ antibody treatment
    Edmond Teng
    Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Neurobiol Dis 43:565-75. 2011
    ..These results corroborate previous analyses of [F-18]FDDNP PET imaging in clinical populations...
  25. pmc Structural selectivity of human SGLT inhibitors
    Charles S Hummel
    Department of Physiology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 1751, USA
    Am J Physiol Cell Physiol 302:C373-82. 2012
    ..Therefore, the pharmacophore must include variations in both the structure of the sugar and the aglycone...
  26. ncbi request reprint Effects of a 14-day healthy longevity lifestyle program on cognition and brain function
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, Los Angeles, CA 90024, USA
    Am J Geriatr Psychiatry 14:538-45. 2006
    ..The objective of this study was to determine the effects of a 14-day healthy longevity lifestyle program on cognition and cerebral metabolism in people with mild age-related memory complaints...
  27. doi request reprint PET of brain prion protein amyloid in Gerstmann-Sträussler-Scheinker disease
    Vladimir Kepe
    David Geffen School of Medicine at UCLA, Los Angeles, Calif 90095 6948, USA
    Brain Pathol 20:419-30. 2010
    ....
  28. ncbi request reprint Exploring a mathematical model for the kinetics of beta-amyloid molecular imaging probes through a critical analysis of plaque pathology
    Kooresh Shoghi-Jadid
    Department of Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    Mol Imaging Biol 8:151-62. 2006
    ..The bias may be partially overcome through evaluation in conjunction with other measures of AD progression including cerebral glucose metabolism rate, neuronal cell loss, and activated inflammatory presence...
  29. ncbi request reprint High-yield, automated radiosynthesis of 2-(1-{6-[(2-[18F]fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile ([18F]FDDNP) ready for animal or human administration
    Jie Liu
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, University of California Los Angeles, 10833 Le Conte Avenue CHS B2 086, Los Angeles, CA 90095, USA
    Mol Imaging Biol 9:6-16. 2007
    ....
  30. ncbi request reprint Synthesis of 4-(5-[18F]fluoromethyl-3-phenylisoxazol-4-yl)benzenesulfonamide, a new [18F]fluorinated analogue of valdecoxib, as a potential radiotracer for imaging cyclooxygenase-2 with positron emission tomography
    Tatsushi Toyokuni
    Crump Institute for Molecular Imaging and LA Tech Center, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, CA 90095, USA
    Bioorg Med Chem Lett 15:4699-702. 2005
    ....
  31. ncbi request reprint In vivo brain imaging of tangle burden in humans
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles School of Medicine, Los Angeles, CA, USA
    J Mol Neurosci 19:323-7. 2002
    ....
  32. pmc Postmortem 3-D brain hemisphere cortical tau and amyloid-β pathology mapping and quantification as a validation method of neuropathology imaging
    Lojze M Smid
    David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 6948, USA
    J Alzheimers Dis 36:261-74. 2013
    ..This work offers a mapping brain model applicable to all imaging probes for verification of imaging results with Aβ and/or tau neuropathology brain distribution using immunohistochemistry, fluorescence microscopy, and autoradiography...
  33. pmc PET imaging of neuropathology in tauopathies: progressive supranuclear palsy
    Vladimir Kepe
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095 6948, USA
    J Alzheimers Dis 36:145-53. 2013
    ..In this work, we evaluate in vivo [18F]FDDNP labeling of brain neuropathology, primarily tau fibrillar aggregates, in patients with progressive supranuclear palsy (PSP), a human tauopathy usually lacking amyloid-β deposits...
  34. pmc Molecular imaging of lymphoid organs and immune activation by positron emission tomography with a new [18F]-labeled 2'-deoxycytidine analog
    Caius G Radu
    Department of Molecular and Medical Pharmacology, 23 120 Center for Health Sciences, Los Angeles, California 90095, USA
    Nat Med 14:783-8. 2008
    ..These data support the use of [(18)F]FAC PET for immune monitoring and suggest a wide range of clinical applications in immune disorders and in certain types of cancer...
  35. ncbi request reprint Radiation dose estimates in humans for (11)C-acetate whole-body PET
    Marc A Seltzer
    Department of Molecular and Medical Pharmacology, Ahmanson Biological Imaging Center, University of California at Los Angeles School of Medicine, Los Angeles, California, USA
    J Nucl Med 45:1233-6. 2004
    ..Dynamic whole-body (11)C-acetate PET was therefore performed on 6 healthy human volunteers. Measured dose estimates for all target organs were compared with the existing ORISE values...
  36. ncbi request reprint Seeing is believing: neuroimaging adds to our understanding of cerebral pathology
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, Alzheimer s Disease Center, University of California, Los Angeles, California 90024, USA
    Curr Opin Psychiatry 19:564-9. 2006
    ..The purpose of this review is to provide background behind these developments and update readers on new findings...
  37. pmc A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss
    Robert M Cohen
    Department of Psychiatry and Behavioral Neurosciences, S Mark Taper Imaging Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Neurosci 33:6245-56. 2013
    ..These results demonstrate progressive neurodegeneration of the Alzheimer type in these animals. The TgF344-AD rat fills a critical need for a next-generation animal model to enable basic and translational AD research...
  38. ncbi request reprint Investigation of a new input function validation approach for dynamic mouse microPET studies
    Sung Cheng Huang
    Department of Molecular and Medical Pharmacology, UCLA David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, USA
    Mol Imaging Biol 6:34-46. 2004
    ..We introduced the theoretical basis and used computer simulations to show the capability of a new approach that requires only a small number of blood samples per mouse but uses multiple animals...
  39. pmc Functional expression of SGLTs in rat brain
    Amy S Yu
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, Universityof California Los Angeles, California 90095 1751, USA
    Am J Physiol Cell Physiol 299:C1277-84. 2010
    ..4-FDG PET imaging also established that this BBB-permeable SGLT tracer now offers a functional imaging approach in humans to assess regulation of SGLT activity in health and disease...
  40. doi request reprint High-pressure, compact, modular radiosynthesizer for production of positron emitting biomarkers
    Bernard Amaraesekera
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Appl Radiat Isot 78:88-101. 2013
    ....
  41. pmc Amyloid-β positron emission tomography imaging probes: a critical review
    Vladimir Kepe
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, CA 90095, USA
    J Alzheimers Dis 36:613-31. 2013
    ....
  42. pmc Automated VOI Analysis in FDDNP PET Using Structural Warping: Validation through Classification of Alzheimer's Disease Patients
    Moses Q Wilks
    Department of Biomathematics, David Geffen School of Medicine at UCLA, Box 951766, Los Angeles, CA 90095, USA
    Int J Alzheimers Dis 2012:512069. 2012
    ..This suggests that this automated method can remove variance in measurements of PET data and can facilitate accurate, high-throughput image analysis...
  43. ncbi request reprint Practical and reliable synthesis of 1,3,4,6-tetra-O-acetyl-2-O-trifluoromethanesulfonyl-beta-D-mannopyranose, a precursor of 2-deoxy-2-[18F]fluoro-D-glucose (FDG)
    Tatsushi Toyokuni
    Crump Institute of Molecular Imaging and LA Tech Center, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, CA 90230, USA
    Mol Imaging Biol 6:324-30. 2004
    ..To develop a practical and reliable synthesis of 1,3,4,6-tetra-O-acetyl-2-O-trifluoromethanesulfonyl-beta-D-mannopyranose (mannose triflate), a precursor of 2-deoxy-2-[18F]fluoro-D-glucose (FDG)...
  44. pmc Mood, cognition and in vivo protein imaging: the emerging nexus in clinical neuroscience
    Anand Kumar
    Department of Psychiatry, the Semel Institute for Neuroscience, University of California, Los Angeles, CA 90024, USA
    Int J Geriatr Psychiatry 23:555-63. 2008
    ..Disorders of mood and cognition overlap in the elderly and there is an emerging consensus that both groups of disorders share neurobiological substrates...
  45. pmc Specific estrogen sulfotransferase (SULT1E1) substrates and molecular imaging probe candidates
    Graham B Cole
    Departmentsof Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, CA 90095 6948, USA
    Proc Natl Acad Sci U S A 107:6222-7. 2010
    ..Because this and other members of this family presenting specificity for SULT1E1 can be labeled with carbon-11 or fluorine-18, in vivo assays of SULT1E1 functional activity are now feasible in humans...
  46. pmc Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation
    John M Ringman
    Mary S Easton Center for Alzheimer s Disease Research, UCLA Department of Neurology, Los Angeles, CA, United States
    Neurosci Lett 487:287-92. 2011
    ..We describe biochemical, imaging, and neuropathological changes in a pedigree with a novel PSEN1 mutation. This allows us to validate the pathogenicity of this mutation and the indices used to assess AD...
  47. ncbi request reprint Metabolic maturation of the brain: a study of local cerebral protein synthesis in the developing cat
    David A Hovda
    Department of Surgery, Division of Neurosurgery, UCLA, CA 90095 7039, USA
    Brain Res 1113:54-63. 2006
    ..We discuss the meaning of these maturational profiles in terms of time course of morphological development and of maturation of behavior in the cat. Correlations with findings in other mammalian species are also discussed...
  48. pmc Positron emission tomography of brain β-amyloid and τ levels in adults with Down syndrome
    Linda D Nelson
    Department of Psychiatry and Biobehavioral Sciences, and Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles 90024, USA
    Arch Neurol 68:768-74. 2011
    ..For reference, [(18)F]FDDNP binding values and patterns were compared with those from patients with Alzheimer disease and cognitively intact control participants...
  49. ncbi request reprint Synthesis of a new heterobifunctional linker, N-[4-(aminooxy)butyl]maleimide, for facile access to a thiol-reactive 18F-labeling agent
    Tatsushi Toyokuni
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California 90095 1770, USA
    Bioconjug Chem 14:1253-9. 2003
    ....
  50. ncbi request reprint Positron-emission tomography reporter gene expression imaging in rat myocardium
    Masayuki Inubushi
    Department of Molecular and Medical Pharmacology, The Crump Institute for Molecular Imaging, University of California, Los Angeles 90095 1735, USA
    Circulation 107:326-32. 2003
    ....
  51. ncbi request reprint Safety-catch linker strategies for the production of radiopharmaceuticals labeled with positron-emitting isotopes
    Derek Maclean
    Affymax Research Institute, 4001 Miranda Avenue, Palo Alto, California 94304, USA
    J Am Chem Soc 125:10168-9. 2003
    ..This technique is expected to lead to more widespread use of positron emission tomography for the in vivo analysis of compound behavior...
  52. ncbi request reprint Molecular-imaging probe 2-(1-[6-[(2-fluoroethyl)(methyl) amino]-2-naphthyl]ethylidene) malononitrile labels prion plaques in vitro
    Mara Bresjanac
    Laboratory for Neuronal Plasticity and Regeneration, Institute of Pathophysiology, University of Ljubljana, SI 1000 Ljubljana, Slovenia
    J Neurosci 23:8029-33. 2003
    ..Our results show that FDDNP reliably identifies all prion plaques, including small cluster-plaques in vCJD. This finding may open new in vivo diagnostic possibilities for vCJD...
  53. ncbi request reprint Flurbiprofen derivatives in Alzheimer's disease: synthesis, pharmacokinetic and biological assessment of lipoamino acid prodrugs
    Rosario Pignatello
    Dipartimento di Scienze Farmaceutiche Università degli Studi di Catania, Viale A Doria, 6 95125 Catania, Italy
    Bioconjug Chem 19:349-57. 2008
    ....
  54. ncbi request reprint The 2,6-disubstituted naphthalene derivative FDDNP labeling reliably predicts Congo red birefringence of protein deposits in brain sections of selected human neurodegenerative diseases
    Lojze M Smid
    Laboratory for Neural Plasticity and Regeneration, Institute of Pathophysiology, University of Ljubljana, Ljubljana, Slovenia
    Brain Pathol 16:124-30. 2006
    ..Our findings may be of significant value for the detection of neuropathological aggregates with [F-18]FDDNP in some of these disorders in the living brain of human subjects...
  55. ncbi request reprint Positron emission tomography imaging of adenoviral-mediated transgene expression in liver cancer patients
    Ivan Penuelas
    Department of Nuclear Medicine, Clinica Universitaria de Navarro, Pamplona, Spain
    Gastroenterology 128:1787-95. 2005
    ....